These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

469 related items for PubMed ID: 12100935

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation.
    Anderson PR, Hanlon AL, Movsas B, Hanks GE.
    Int J Radiat Oncol Biol Phys; 1997 Dec 01; 39(5):1025-30. PubMed ID: 9392540
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A.
    Urol Int; 1996 Dec 01; 56 Suppl 1():13-7. PubMed ID: 8776812
    [Abstract] [Full Text] [Related]

  • 25. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
    Egawa S, Takashima R, Matsumoto K, Mizoguchi H, Kuwao S, Baba S.
    Jpn J Clin Oncol; 2000 Jan 01; 30(1):21-6. PubMed ID: 10770564
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T, Campbell J, Bryant C, Lynch W.
    Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950
    [Abstract] [Full Text] [Related]

  • 29. Radiotherapy and short-term androgen deprivation for localized prostate cancer.
    Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, Leibenhaut MH, Husain SM, Rotman M, Souhami L, Sandler HM, Shipley WU.
    N Engl J Med; 2011 Jul 14; 365(2):107-18. PubMed ID: 21751904
    [Abstract] [Full Text] [Related]

  • 30. Usefulness of combined androgen blockade therapy with gonadotropin-releasing hormone antagonist for bone metastatic prostate cancer with pretreatment prostate-specific antigen level ≥ 50 ng/mL.
    Kashiwabara T, Suda S.
    BMC Cancer; 2018 May 31; 18(1):619. PubMed ID: 29855278
    [Abstract] [Full Text] [Related]

  • 31. Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy.
    Fujii Y, Kawakami S, Masuda H, Kobayashi T, Hyochi N, Kageyama Y, Kihara K.
    BJU Int; 2006 Jun 31; 97(6):1184-9. PubMed ID: 16686709
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N, Smolkin ME, Bissonette E, Theodorescu D.
    Cancer; 2005 Jun 15; 103(12):2499-506. PubMed ID: 15852361
    [Abstract] [Full Text] [Related]

  • 34. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.
    Urology; 2007 Sep 15; 70(3):506-10. PubMed ID: 17905106
    [Abstract] [Full Text] [Related]

  • 35. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K.
    Evid Rep Technol Assess (Summ); 1999 May 15; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [Abstract] [Full Text] [Related]

  • 36. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?
    Mottet N, Lucas C, Sene E, Avances C, Maubach L, Wolff JM.
    Urol Int; 2005 May 15; 75(3):204-8. PubMed ID: 16215305
    [Abstract] [Full Text] [Related]

  • 37. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.
    Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):15-23. PubMed ID: 15337535
    [Abstract] [Full Text] [Related]

  • 38. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Koh Y, Kawashima A, Ujike T, Nagahara A, Fujita K, Kiuchi H, Imamura R, Miyagawa Y, Nonomura N, Uemura M.
    Anticancer Drugs; 2020 Nov 01; 31(10):1099-1102. PubMed ID: 32804697
    [Abstract] [Full Text] [Related]

  • 39. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
    McLeod DG, Johnson CF, Klein E, Peabody JO, Coffield S, Soloway M.
    Urology; 1997 Mar 01; 49(3A Suppl):70-3. PubMed ID: 9123740
    [Abstract] [Full Text] [Related]

  • 40. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer.
    Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B.
    Endocr Rev; 2005 May 01; 26(3):361-79. PubMed ID: 15867098
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.